The closing Plenary of Day 2 at #SLDSummit 2026 is focused on the next wave of therapeutic development in SLD. Metabolic directed and liver directed treatment strategies are being examined in depth, reflecting the rapidly expanding pipeline of potential interventions. Fresh data on metabolic modulation in MASLD and type 2 diabetes are contributing to the evolving evidence base. The discussion is also tackling a key question in cirrhosis care, whether treatment goals should prioritise fibrosis regression or tangible clinical outcomes. A forward thinking exchange is setting the tone as we head into the final day of the Summit. @schattenbergJ

The approval of new drugs for SLD will significantly impact the field, driving a shift towards a more proactive approach to liver health. While challenges remain in terms of healthcare systems and reimbursement, the availability of effective treatments offers a crucial opportunity to improve patient outcomes and address the growing burden. @schattenbergJ #SLDSummit

👇

⭐️We are proud to announce that Prof. Dr. Jörn Schattenberg, Director of the Department of Internal Medicine II at Saarland University Hospital, has been elected Chairman of the Scientific Committee of the United European Gastroenterology @my_ueg for the term 2026 - 2029! 👏 Dr. Schattenberg, whom EASL proudly nominated for this position, also serves on our EASL Policy, Public Health and Advocacy Committee, contributing his expertise to guide the Association’s policy and public affairs efforts. Congratulations, @schattenbergJ , on this well-deserved recognition! 🎉